These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36280874)

  • 1. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
    Alcoceba M; Stewart JP; García-Álvarez M; Díaz LG; Jiménez C; Medina A; Chillón MC; Gazdova J; Blanco O; Díaz FJ; Peñarrubia MJ; Fernández S; Montes C; Cabero A; Caballero MD; García-Sanz R; González M; González D; Tamayo P; Gutiérrez NC; García-Sancho AM; Sarasquete ME
    Br J Haematol; 2024 Jul; 205(1):109-121. PubMed ID: 38811363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
    Herrera AF; Tracy S; Croft B; Opat S; Ray J; Lovejoy AF; Musick L; Paulson JN; Sehn LH; Jiang Y
    Blood Adv; 2022 Mar; 6(6):1651-1660. PubMed ID: 35086141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 5. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    Kurtz DM; Scherer F; Jin MC; Soo J; Craig AFM; Esfahani MS; Chabon JJ; Stehr H; Liu CL; Tibshirani R; Maeda LS; Gupta NK; Khodadoust MS; Advani RH; Levy R; Newman AM; Dührsen U; Hüttmann A; Meignan M; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
    J Clin Oncol; 2018 Oct; 36(28):2845-2853. PubMed ID: 30125215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Li M; Ding N; Mi L; Shi Y; Du X; Yi Y; Yang L; Liu W; Zhu J
    Leuk Lymphoma; 2022 Mar; 63(3):608-617. PubMed ID: 34751093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis.
    Yao L; Xu H; Wo J; Zhao M; Liu Z; Dong T; Xiao S
    Clin Exp Med; 2022 Feb; 22(1):1-7. PubMed ID: 33990849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
    Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
    J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
    Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH
    Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
    Kwok M; Wu SP; Mo C; Summers T; Roschewski M
    Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
    Liang JH; Wu YF; Shen HR; Li Y; Liang JH; Gao R; Hua W; Shang CY; Du KX; Xing TY; Zhang XY; Wang CX; Zhu LQ; Shao YW; Li JY; Wu JZ; Yin H; Wang L; Xu W
    Leukemia; 2024 Jul; 38(7):1541-1552. PubMed ID: 38750139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
    Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
    Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
    Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
    Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
    Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
    Mutter JA; Alig SK; Esfahani MS; Lauer EM; Mitschke J; Kurtz DM; Kühn J; Bleul S; Olsen M; Liu CL; Jin MC; Macaulay CW; Neidert N; Volk T; Eisenblaetter M; Rauer S; Heiland DH; Finke J; Duyster J; Wehrle J; Prinz M; Illerhaus G; Reinacher PC; Schorb E; Diehn M; Alizadeh AA; Scherer F
    J Clin Oncol; 2023 Mar; 41(9):1684-1694. PubMed ID: 36542815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Heger JM; d'Hargues Y; Kleinert F; Mattlener J; Weiss J; Franzen F; Becker C; Becker K; Gödel P; Schmiel M; Meinel J; Flümann R; Simon F; Reinhardt HC; Borchmann P; Borchmann S; Balke-Want H; Knittel G; von Tresckow B
    Eur J Haematol; 2024 Jun; 112(6):957-963. PubMed ID: 38369814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.